{"id":721,"date":"2020-09-29T17:43:55","date_gmt":"2020-09-29T15:43:55","guid":{"rendered":"http:\/\/kdog.eu\/?page_id=721"},"modified":"2020-10-15T11:35:42","modified_gmt":"2020-10-15T09:35:42","slug":"etude-clinique-en","status":"publish","type":"page","link":"https:\/\/kdog.eu\/index.php\/en\/etude-clinique-en\/","title":{"rendered":"Etude clinique – EN"},"content":{"rendered":"

The clinical study<\/h3>\n
\n\t
\n

The KDOG team validated a proof of concept in 2017-2018 with 2 dogs which in more than 90% of cases found the sample carried by sick women among samples of women without cancer. This is exceptional and seems to prove that the dogs do detect something, but it is not enough. We must now move from a concept to a rigorous, repeatable, scientifically validated by the medical community progress, which requires a clinical study. This clinical study, carried out in a multicentre setting, began in early 2020.<\/p>\n<\/blockquote>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>

A word from Anne Tardivon, Principal Investigator<\/h3>\n
\n\t<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>
\n
\n\t

Anne TARDIVON<\/strong> has been working as a radiologist in Cancer Centres since 1992, and at the Curie Institute since 2002. Specialising in breast imaging, she is the principal investigator of the clinical study of the KDOG project.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

<\/i><\/span>